Eisai has submitted a marketing authorisation application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. The MAA is for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia) with confirmed amyloid pathology in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!